March 27, 2024
New York's attorney general was one of three objectors Tuesday to a provision in Sandoz's proposed $265 million settlement with a class of drug wholesalers in Pennsylvania federal court that they say will delay any future generic-drug price-fixing litigation deals by taxing agreements over $119.25 million.
March 14, 2024
A group of direct purchasers of generic drugs has asked a Pennsylvania federal court for approval of a $265 million settlement with Swiss drugmaker Sandoz over allegations of federal antitrust violations.
February 29, 2024
Swiss generic drug and biosimilar manufacturer Sandoz announced Thursday that two of its subsidiaries have reached a $265 million settlement with the direct purchasers of generic medications to resolve allegations of federal antitrust violations.
February 14, 2024
A Pennsylvania federal judge granted preliminary approval Wednesday to settlements in which two makers and one distributor of generic drugs agreed to pay a combined $45 million to resolve allegations they colluded to fix the prices of medications, including those used to treat glaucoma, high blood pressure and high cholesterol.
February 01, 2024
The Judicial Panel on Multidistrict Litigation has sent a trio of cases from state-level enforcers back to federal court in Connecticut, separating them from the sprawling MDL centralized in Pennsylvania over claims of price fixing in the generic drug industry.
January 23, 2024
Generic-drug makers Apotex Corp., Heritage Pharmaceuticals Ltd. and Breckenridge Pharmaceutical Inc. have each agreed to shell out a combined $45 million to settle allegations they colluded to fix the prices of many medications, according to a trio of motions filed Tuesday in multidistrict litigation in Pennsylvania federal court.
January 17, 2024
Generic-drug makers steeped in antitrust multidistrict litigation are asking for an order enforcing a months-old deadline for documents that most states have ignored, according to a memorandum filed in Pennsylvania federal court.
December 07, 2023
The Pennsylvania federal judge overseeing sprawling multidistrict litigation against generic-drug makers on Thursday told the U.S. Judicial Panel on Multidistrict Litigation that she does not recommend transferring state enforcer actions out of the MDL yet, saying there's more the court can do to get the cases ready for trial or to tee up settlement talks.
November 02, 2023
State enforcers accusing several generic drugmakers of price-fixing asked the Judicial Panel on Multidistrict Litigation to move their case back to Connecticut federal court, saying legislation signed by President Joe Biden last year spares state enforcers from the MDL process.
October 04, 2023
Novartis AG completed the planned spinoff of its Sandoz unit on Wednesday, after state enforcers and others withdrew their bid to block the move over concerns about recovering alleged overcharges from a sprawling conspiracy to fix generic drug prices.